Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

AbbVie Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The period under review demonstrates significant fluctuations in economic profit. Net operating profit after taxes (NOPAT) exhibited a substantial increase from 2020 to 2021, followed by a decline in subsequent years, with a partial recovery in the most recent period. Simultaneously, the cost of capital consistently increased throughout the observed timeframe. Invested capital generally decreased, although a slight increase is noted between 2023 and 2024.

NOPAT Trend
NOPAT increased dramatically from US$4,455 million in 2020 to US$12,362 million in 2021. This was followed by a decrease to US$11,543 million in 2022, and a more substantial decline to US$3,292 million in 2023. A modest recovery to US$4,563 million occurred in 2024, remaining near the level observed in 2020.
Cost of Capital Trend
The cost of capital experienced a steady upward trend, increasing from 8.86% in 2020 to 10.84% in 2024. This consistent rise suggests increasing financing costs or perceived risk over the period.
Invested Capital Trend
Invested capital decreased from US$103,725 million in 2020 to US$68,204 million in 2023, indicating a reduction in the capital employed by the business. A slight increase to US$69,263 million was observed in 2024, potentially signaling a stabilization or minor reinvestment.
Economic Profit Trend
Economic profit was negative in 2020 at US$-4,740 million. It turned positive in 2021 and 2022, reaching US$2,934 million and US$2,884 million respectively. However, it became negative again in 2023 (US$-4,070 million) and remained negative in 2024 (US$-2,943 million). The negative economic profit in 2020, 2023, and 2024 indicates that the business was not generating returns exceeding its cost of capital in those years.

The interplay between NOPAT, cost of capital, and invested capital significantly impacted economic profit. The initial increase in NOPAT in 2021, coupled with a relatively lower cost of capital, drove positive economic profit. However, the subsequent decline in NOPAT and the concurrent increase in the cost of capital reversed this trend, resulting in negative economic profit in later periods. The decreasing invested capital may have partially offset the impact of declining NOPAT, but was insufficient to maintain positive economic profit.


Net Operating Profit after Taxes (NOPAT)

AbbVie Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings attributable to AbbVie Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in restructuring reserve2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in restructuring reserve.

3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


The financial data reveals significant fluctuations in key profitability metrics over the five-year period from 2020 to 2024. Net earnings attributable to the company show a marked increase between 2020 and 2021, more than doubling from 4,616 million USD to 11,542 million USD. This upward trend continued slightly into 2022, reaching 11,836 million USD. However, a sharp decline is observed in 2023, where net earnings drop to 4,863 million USD, followed by a further decrease in 2024 to 4,278 million USD.

Similarly, net operating profit after taxes (NOPAT) exhibits a strong growth trajectory in the initial years, rising from 4,455 million USD in 2020 to 12,362 million USD in 2021, before slightly decreasing to 11,543 million USD in 2022. In contrast to the early upward momentum, NOPAT experiences a significant fall in 2023 to 3,292 million USD, although it recovers somewhat in 2024 to 4,563 million USD.

Net Earnings Attributable to the Company
Demonstrated substantial growth in the first two years, peaking in 2022.
Experienced a pronounced decline in the subsequent years, reaching the lowest point in 2024 within the presented timeframe.
Net Operating Profit After Taxes (NOPAT)
Followed a similar pattern to net earnings, with rapid growth through 2021, slight reduction in 2022.
Showed a sharp decline beginning in 2023, with modest recovery in 2024 albeit remaining well below earlier peak levels.

Overall, the data points toward a period of strong profitability gains up to 2022, followed by notable erosion in both net earnings and NOPAT over the last two years. The decline in profitability metrics during 2023 and 2024 suggests the presence of operational challenges or market conditions adversely impacting financial performance. The partial resurgence of NOPAT in 2024 hints at potential stabilization or early signs of financial recovery.


Cash Operating Taxes

AbbVie Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax expense (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Expense (Benefit) Trend
The income tax expense exhibited significant volatility over the analyzed period. It began with a notable benefit of -$1,224 million at the end of 2020, indicating a tax gain or credit that reduced tax burden during that year. This reversed sharply in 2021 to a tax expense of $1,440 million, then further increased to $1,632 million in 2022. In 2023, it slightly decreased but remained high at $1,377 million. However, in 2024, the income tax expense again turned negative, showing a benefit of -$570 million. This pattern suggests fluctuating tax positions or adjustments possibly due to changes in tax regulations, earnings variations, or deferred tax accounting impacts.
Cash Operating Taxes Trend
The cash operating taxes consistently increased from 2020 through 2023, indicating increasing cash payments for taxes despite fluctuations in reported income tax expense. In 2020, cash taxes were $1,585 million, which rose significantly each year to reach $4,625 million in 2023. However, in 2024, there was a notable decline in cash operating taxes to $1,339 million, which is substantially lower than the prior years. This decline could suggest a one-time tax payment adjustment, changes in taxable income, tax credits utilization, or other operational tax strategies impacting cash outflows.
General Observations
While reported income tax expenses fluctuated between benefits and expenses, cash taxes paid showed a general increasing trend until a sharp drop in 2024. The divergence between income tax expense and cash operating taxes through the years implies differences between accounting recognition of tax expenses and actual tax payments, which is common in companies with complex tax structures. The decline in both income tax expense and cash operating taxes in 2024 may indicate significant tax planning outcomes or shifts in profitability affecting tax liabilities.

Invested Capital

AbbVie Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings
Current portion of long-term debt and finance lease obligations
Long-term debt and finance lease obligations, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Restructuring reserve3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Noncontrolling interest
Adjusted stockholders’ equity
Construction in progress6
Available-for-sale investment securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of restructuring reserve.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investment securities.


The financial data over the provided periods reveal several significant trends related to debt, equity, and capital structure.

Total reported debt & leases
The total reported debt and leases exhibit a decreasing trend from 87,063 million USD at the end of 2020 to 60,286 million USD by the end of 2023, reflecting a substantial reduction in leverage over the first four years. However, in 2024, there is a noticeable increase to 68,019 million USD, indicating a reversal of the prior downward trend in debt levels.
Stockholders’ equity
Stockholders' equity initially increases from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. Subsequently, it declines sharply to 10,360 million USD in 2023 and continues to deteriorate significantly in 2024, dropping to 3,325 million USD. This steep decrease in equity over the last two years suggests increased challenges with retained earnings or potential capital losses.
Invested capital
Invested capital shows a consistent downward trajectory, reducing from 103,725 million USD in 2020 to 68,204 million USD in 2023. Unlike other trends, invested capital appears to stabilize in 2024 with a slight increase to 69,263 million USD, signaling a possible floor or minor recovery in invested assets or operational capital use.

Overall, the data suggest a focused effort on debt reduction from 2020 to 2023 accompanied by increasing equity till 2022. However, the last two years highlight financial stress with declining equity and rising debt, raising concerns about the company’s capital structure stability and financial leverage. The decline and subsequent stabilization in invested capital corroborate a contraction phase followed by an attempt to maintain or increment operational investment.


Cost of Capital

AbbVie Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

AbbVie Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The economic spread ratio exhibited considerable fluctuation between 2020 and 2024. Initially negative, it turned positive for two consecutive years before reverting to negative values. This pattern is closely linked to the concurrent changes in economic profit and invested capital.

Economic Spread Ratio Trend
In 2020, the economic spread ratio was -4.57%, indicating that the company’s return on invested capital was less than its cost of capital. A significant improvement occurred in 2021, with the ratio rising to 3.06%, signifying a positive economic spread. This positive trend continued into 2022, reaching 3.51%. However, the ratio declined sharply in 2023 to -5.97%, and remained negative in 2024 at -4.25%. This suggests a weakening in the company’s ability to generate returns exceeding its cost of capital in the latter two years.
Relationship with Economic Profit
The economic spread ratio’s movement mirrors the trend in economic profit. Negative economic profit in 2020 and 2023-2024 corresponds with negative economic spread ratios. Conversely, positive economic profit in 2021 and 2022 aligns with positive economic spread ratios. This confirms that the economic spread ratio is directly influenced by the company’s ability to generate economic profit.
Relationship with Invested Capital
Invested capital decreased consistently from 2020 to 2023, falling from US$103,725 million to US$68,204 million. While invested capital saw a slight increase in 2024 to US$69,263 million, it did not recover to previous levels. The decline in invested capital, coupled with the shift to negative economic profit in 2023 and 2024, likely contributed to the negative economic spread ratios observed during those periods. The increase in 2024 did not fully offset the negative economic profit, resulting in a continued negative spread.

Overall, the analysis indicates a period of initial improvement in value creation, followed by a deterioration. The company’s performance in generating returns above its cost of capital has become increasingly challenged in recent years, as evidenced by the declining and ultimately negative economic spread ratio.


Economic Profit Margin

AbbVie Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Net revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin exhibited considerable fluctuation between 2020 and 2024. Initial observations reveal a shift from negative economic profit to positive values, followed by a return to negative figures. A detailed examination of the economic profit margin and its underlying components provides further insight into these trends.

Economic Profit Margin Trend
In 2020, the economic profit margin stood at -10.35%. A substantial improvement was noted in 2021, with the margin increasing to 5.22%. This positive trend continued modestly into 2022, reaching 4.97%. However, the margin experienced a significant decline in 2023, falling to -7.49%. This downward trajectory persisted into 2024, with the economic profit margin settling at -5.22%.
Relationship to Net Revenues
Net revenues demonstrated an overall increasing trend throughout the period, rising from US$45,804 million in 2020 to US$56,334 million in 2024. Despite this revenue growth, the economic profit margin did not consistently benefit. The negative economic profit margins in 2020, 2023, and 2024 suggest that the cost of capital, or other factors impacting economic profit, outweighed the gains from increased revenue during those years.
Economic Profit Fluctuations
The economic profit itself moved from -US$4,740 million in 2020 to a positive US$2,934 million in 2021 and US$2,884 million in 2022. The subsequent decline to -US$4,070 million in 2023 and -US$2,943 million in 2024 mirrors the deterioration observed in the economic profit margin. This indicates that the absolute economic profit generated is closely tied to the margin’s performance.

The period under review highlights a volatile relationship between revenue generation and economic profitability. While revenue increased overall, maintaining positive economic profit proved challenging, particularly in 2020, 2023, and 2024. Further investigation into the factors influencing economic profit, such as cost of capital and operational efficiency, would be necessary to fully understand these fluctuations.